1818428-24-8

1818428-24-8 structure

Name: VCE-004.8
Chemical Name: VCE-004.8
CAS Number: 1818428-24-8
Molecular Formula: C₂₈H₃₅NO₃
Molecular Weight: 433.58
Catalog: Signaling Pathways Cell Cycle/DNA Damage PPAR
Create Date: 2019-09-09 19:37:48
Modify Date: 2024-01-10 20:32:52
VCE-004.8, a semi-synthetic multitarget cannabinoquinoid, is a specific PPARγ and CB2 receptor dual agonist with potent anti-inflammatory activity[1]. VCE-004.8 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity[2].

Name	VCE-004.8
Synonyms	VCE-004.8

Description	VCE-004.8, a semi-synthetic multitarget cannabinoquinoid, is a specific PPARγ and CB2 receptor dual agonist with potent anti-inflammatory activity[1]. VCE-004.8 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity[2].
Related Catalog	Signaling Pathways >> Cell Cycle/DNA Damage >> PPAR Research Areas >> Inflammation/Immunology Signaling Pathways >> Metabolic Enzyme/Protease >> HIF/HIF Prolyl-Hydroxylase Research Areas >> Metabolic Disease Signaling Pathways >> GPCR/G Protein >> Cannabinoid Receptor
Target	PPARγ CB2
In Vivo	VCE-004.8 ( injection; 20 mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. VCE-004.8 can also significantly ameliorate glucose tolerance, reduce leptin levels (a marker of adiposity) and increase adiponectin and incretins (GLP-1 and GIP) levels[1].
References	[1]. Navarrete C, et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. J Neuroinflammation. 2018 Mar 1;15(1):64. [2]. Palomares B, et al. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. Sci Rep. 2018 Oct 31;8(1):16092.

Molecular Formula	C₂₈H₃₅NO₃
Molecular Weight	433.58